<DOC>
	<DOCNO>NCT00562666</DOCNO>
	<brief_summary>For patient hepatocellular carcinoma , surgery curative procedure possible palliative measure could apply ( chemoembolization , target drug , best supportive care , etc ) . In ICAR study , increase dos cell therapy product evaluate patient palliative setting . All patient one hepatic intra-arterial injection immunological cell ( gamma-delta T lymphocyte ) evaluate safety .</brief_summary>
	<brief_title>Immunotherapy Hepatocellular Carcinoma With Gamma Delta T Cells</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Adult 18 Hepatocellular carcinoma histologically proven , least one measurable tumor Non operable tumor Alfa foeto protein &gt; 400 ng/ml Other treatment ( surgery , chemoembolization ) non indicate Chemoembolization non indicate due good performance status ( WHO 1 ) tumor volume Performance status WHO &lt; 2 Life expectancy &gt; 3 month Non inclusion Criteria : Extra hepatic metastasis Severe hepatopathy ( Child B C ) Virus B C chronic hepatitis Chronic cardiac failure Uncontrolled severe infectious disease Other cancer , consider cure Positive serology HIV HTLV Leucocytes &lt; 3000/mm3 neutrophil &lt; 1500/mm3 Platelets &lt; 80000/mm3 Serum creatinine &gt; 110 µmol/L Bilirubin &gt; 35 µmol/L AST , ALT , alkaline phosphatase &gt; 5N Current immunosuppressive treatment Impossibility comply schedule followup Anatomical situation permit selective injection product cell therapy Pregnant breastfeed woman , use adequate effective contraceptive method Exclusion Criterion : Insufficient number gamma delta lymphocytes expansion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>cell therapy</keyword>
	<keyword>T lymphocyte</keyword>
	<keyword>hepatic intra-arterial injection</keyword>
</DOC>